NB 1011
Alternative Names: NB1011; ThymectacinLatest Information Update: 23 May 2022
At a glance
- Originator NewBiotics
- Developer Kiadis Pharma
- Class Antineoplastics; Nucleosides; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 23 May 2022 Phase I/II development is ongoing in Solid tumours (Metastatic disease, Late-stage disease) in Canada and USA (IV) (NCT00248404)
- 23 May 2022 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in Canada (IV) Before September 2005 (NCT00248404)
- 23 May 2022 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Late-stage disease) in USA (IV) Before September 2005 (NCT00248404)